The biotech is developing an experimental drug for the most common of a family of disorders all caused by errors in ...

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...

While J&J expects tariffs will cost it $400 million this year, the company maintained its earnings estimate and upped its ...

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it ...

As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of U.S.

The Atlas-backed company plans to liquidate its assets, including an experimental drug for chronic spontaneous urticaria it ...

Using integrated lab, claims, and EMR data, the manufacturer can pull in test results and deploy NLP on the unstructured EMR ...

Experts say the layoffs are already causing issues in drug development — and things may get far worse without critical ...

The Commerce Department has begun a so-called Section 232 investigation into the national security effects of the U.S.

Cellular Therapies and IDRx, crossed the $1 billion mark, a notable decrease from the six seen during the same period last ...

Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump ...

Wall Street analysts said the results for Verve’s therapy appeared competitive on efficacy, while avoiding any major safety ...